effect overlay
activetrials
Stroke

A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
 

HREC: 2023.046
Principal Investigator: Prof Bruce Campbell
Coordinator contact: Nicola Parsons
Funding: Commercial

"A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic
stroke or high-risk TIA"
 

HREC: 2023.051
Principal Investigator: Prof Bruce Campbell
Coordinator contact: Laura Fiscchia
Funding: Commercial
Stroke

Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
 

HREC: 2023.132
Principal Investigator: Prof Bruce Campbell
Coordinator contact: David Jackson
Funding: Non-Commercial
Stroke

A Phase II, Multicenter, Double Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose Study to Determine the Safety, Preliminary Efficacy,and Pharmacokinetics of ARG 007 in Acute Ischemic Stroke Patients
 

HREC: 2023.189
Principal Investigator: Prof Bruce Campbell
Coordinator contact:
Funding: Commercial